Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India
Background: India currently has the second largest burden of infections due to COVID-19. Health Care Worker (HCW) shortages are endemic to Indian healthcare. It should therefore be a huge priority to protect this precious resource as a critical component of the systemic response to this pandemic. Advisories from the Indian Council of Medical Research (ICMR) have focused on using hydroxychloroquine prophylaxis against COVID-19 in at risk HCW. This prophylaxis strategy has no evidence. In further jeopardy there appear to insubstantial attempts to build this evidence as well. In this connection, we commissioned a survey within our Institution to estimate the penetration of hydroxychloroquine (HCQ) use and use this to statistically model the impact of current ongoing studies in India. We also briefly review the literature on HCQ prophylaxis for COVID-19.
Design and methods: A structured survey designed using RedCAP application was disseminated among healthcare professionals employed at an academic referral tertiary care centre via online social media platforms. The survey was kept open for the entire month of June 2020. The survey was additionally used to statistically model the size of studies required to comprehensively address the efficacy of HCQ in this setting.
Results: 522 responses were received, of which 4 were incomplete. The ICMR strategy of 4 or more doses of HCQ was complete only in 15% of HCW in our survey. The majority of respondents were doctors (238, 46%). Amongst all category of responders, only 12% (n=63) received the full course. A majority of those who initiated the chemoprophylaxis with HCQ turned out to be medical professionals (59/63) with neither nurse nor other categories of healthcare workers accessing the medication. The respondents of our institutional survey did not report any life-threatening side effects. Presuming efficacy as per ICMR modelling for new registry trial on the lines of the published case control study, equal allocation between cases and controls and assuming a RR of 1.3.6, the power of such a study would be very low for n=2000 for event rates from 2.5-12.5%.
Conclusion: We report the low penetration of HCQ chemoprophylaxis among the healthcare workers of our institution. We highlight the inherent drawbacks in the study design of current national COVID related trial based on the statistical modelling of our survey results and published literature, and thereby emphasis the need of evidence-based strategies contributing to research policy at national level.
Armocida B, Formenti B, Ussai S, et al. The Italian health system and the COVID-19 challenge. Lancet Public Health 2020;5:e253. doi: 10.1016/S2468-2667(20)30074-8 DOI: https://doi.org/10.1016/S2468-2667(20)30074-8
Tanne JH, Hayasaki E, Zastrow M, et al. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ 2020;368:m1090. doi: 10.1136/bmj.m1090 DOI: https://doi.org/10.1136/bmj.m1090
Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID-19: Viral Genomics, epidemiology, vaccines, and therapeutic interventions. Viruses 2020;12:526. doi: 10.3390/v12050526 DOI: https://doi.org/10.3390/v12050526
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949. doi: 10.1016/j.ijantimicag.2020.105949 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105949
Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020;55:105988. doi: 10.1016/j.ijantimicag.2020.105988 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105988
Ministry of Health and Family Welfare. Advisory on the use of hydroxychloroquine in hospitalised patients with Covid-19. Accessed June 10, 2020. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSC oV2infection.pdf
Indian Council for Medical Research. Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection (in supersession of previous advisory dated 23 Mar 2020). 2020. Available from: https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf
Jha S, Soni A, Siddiqui S, et al. Prevalence of flu-like symptoms and COVID-19 in healthcare workers from India. J Assoc Physicians India 2020;68:27-29.
Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382:2411-8. doi: 10.1056/NEJMoa2012410 DOI: https://doi.org/10.1056/NEJMoa2012410
Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;368:m1849. doi: 10.1136/bmj.m1849 DOI: https://doi.org/10.1136/bmj.m1849
Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;386:m1844. doi: 10.1136/bmj.m1844 DOI: https://doi.org/10.1136/bmj.m1844
Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. JAMA Netw Open 2020;3:e208857. doi: 10.1001/jamanetworkopen.2020.8857 DOI: https://doi.org/10.1001/jamanetworkopen.2020.8857
Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5:1036-41. doi: 10.1001/jamacardio.2020.1834 DOI: https://doi.org/10.1001/jamacardio.2020.1834
James Watson on the behalf of 201 signatories. Open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID19: a multinational registry analysis”. Lancet. 2020 May 22:S0140-6736(20)31180-6. doi: 10.1016/S0140-6736(20)31180-6. PMID: 32450107 and to Richard Horton (editor of The Lancet). Concerns regarding the statistical analysis and data integrity. Available from: https://zenodo.org/record/3871094#.X9zIs-lKhdA
The New York Times [Internet]. Scientists question validity of major hydroxychloroquine study. Accessed June 15, 2020. Available from: https://www.nytimes.com/2020/05/29/health/coronavirus-hydroxychloroquine.html
Science Integrity Digest [Internet]. Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections. Accessed May 29, 2020. Available from: https://scienceintegritydigest.com/2020/03/24/thoughts-on-the-gautret-et-al-paper-about-hydroxychloroquine-and-azithromycin-treatment-of-covid-19-infections/
Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383:517-25. doi: 10.1056/NEJMoa2016638 DOI: https://doi.org/10.1056/NEJMoa2016638
Chatterjee P, Anand T, Singh K, et al. Healthcare workers and SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res 2020. doi: 10.4103/ijmr.IJMR_2234_20 DOI: https://doi.org/10.4103/ijmr.IJMR_2234_20
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should Clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living practice points from the American College of Physicians (Version 1). Ann Intern Med 2020;173:137-42. doi: 10.7326/M20-1998 DOI: https://doi.org/10.7326/M20-1998
Sim MR. The COVID-19 pandemic: major risks to healthcare and other workers on the front line. Occup Environ Med 2020;77:281-2. doi:10.1136/oemed-2020-106567 DOI: https://doi.org/10.1136/oemed-2020-106567
Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020. doi: 10.1016/j.jinf.2020.04.021 DOI: https://doi.org/10.1016/j.jinf.2020.04.021
Zhang J, Yu KF. What’s the relative risk? JAMA 1998;280:1690. doi: 10.1001/jama.280.19.1690 DOI: https://doi.org/10.1001/jama.280.19.1690
Karan A, Negandhi H, Nair R, et al. Size, composition and distribution of human resource for health in India: new estimates using National Sample Survey and Registry data. BMJ Open 2019;9:e025979. doi: 10.1136/bmjopen-2018-025979 DOI: https://doi.org/10.1136/bmjopen-2018-025979
The Washington Post [Internet]. A frantic search for scarce hospital beds as pandemic rages in India. Available from: https://www.washingtonpost.com/world/asia_pacific/india-coronavirus-hospital-beds/2020/06/12/7b538a8a-ab4d-11ea-a43b-be9f6494a87d_story.html
India Today [Internet]. Help healthcare workers, Mumbai doctor appeals; warns of sharp rise in India’s Covid-19 case tally. Available from: https://www.indiatoday.in/india/story/mumbai-doctor-viral-post-kem-appeal-ppe-medical-healthacre-1686629-2020-06-08
Tirupakuzhi Vijayaraghavan BK, Jha V, Rajbhandari D, et al. Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation (HOPE) trial: A structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:754. doi: 10.1186/s13063-020-04679-3 DOI: https://doi.org/10.1186/s13063-020-04679-3
Al‐Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID‐19: The desperate search for effectiveness. Clin Pharmacol Ther 2020;108:766-9. doi: 10.1002/cpt.1874 DOI: https://doi.org/10.1002/cpt.1874
Gupta A, Vijay J, Agstam S. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for hydroxychloroquine induced QTc prolongation? Indian Pacing Electrophysiol J 2020;20:208. doi: 10.1016/j.ipej.2020.06.008 DOI: https://doi.org/10.1016/j.ipej.2020.06.008
Food and Drug Administration. Hydroxychloroquine sulfate (Plaquenil) [package insert]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020;57:279-83. doi: 10.1016/j.jcrc.2020.03.005 DOI: https://doi.org/10.1016/j.jcrc.2020.03.005
Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19. Ann Intern Med 2020;173:287-96. doi: 10.7326/M20-2496 DOI: https://doi.org/10.7326/M20-2496
Infectious Diseases Society of America (IDSA). Infectious Diseases Society of America Guidelines on infection prevention in patients with suspected or known COVID-19. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/
- Abstract views: 415
- PDF: 249
- Supplementary Data: 16
- HTML: 0
Copyright (c) 2020 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.